Research ArticleArticle
Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis
Maxime Dougados, Emily Wood, Laure Gossec, Arnaud Dubanchet, Isabelle Logeart and Désirée van der Heijde
The Journal of Rheumatology November 2015, jrheum.150378; DOI: https://doi.org/10.3899/jrheum.150378
Maxime Dougados
From the Paris Descartes University; Department of Rheumatology-Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP); Institut national de la santé et de la recherche médicale (INSERM; U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique; Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; Pfizer, Paris, France; Statistical Consultancy, Quanticate Ltd., Hitchin, UK; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. Sponsored by Pfizer. Dr. Dougados has received consulting fees from Pfizer and his department has received research grants from Pfizer for this study. Ms. Wood was contracted and paid by Pfizer to provide statistical input to the study and manuscript. Dr. Gossec has received consulting fees from Pfizer. Dr. van der Heijde has received consulting fees and/or research grants from Pfizer. Dr. Dubanchet and Dr. Logeart are employees of Pfizer. Pfizer paid for editorial/medical writing support. M. Dougados, MD, Paris Descartes University, and Department of Rheumatology-Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; E. Wood, MSc, Statistical Consultancy, Quanticate Ltd.; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, and Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; A. Dubanchet, MD, Pfizer; I. Logeart, MD, Pfizer; D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center. Address correspondence to Dr. M. Dougados, Rheumatology B Department, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail: maxime.dougados@cch.aphp.fr. Accepted for publication August 14, 2015.
Emily Wood
From the Paris Descartes University; Department of Rheumatology-Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP); Institut national de la santé et de la recherche médicale (INSERM; U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique; Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; Pfizer, Paris, France; Statistical Consultancy, Quanticate Ltd., Hitchin, UK; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. Sponsored by Pfizer. Dr. Dougados has received consulting fees from Pfizer and his department has received research grants from Pfizer for this study. Ms. Wood was contracted and paid by Pfizer to provide statistical input to the study and manuscript. Dr. Gossec has received consulting fees from Pfizer. Dr. van der Heijde has received consulting fees and/or research grants from Pfizer. Dr. Dubanchet and Dr. Logeart are employees of Pfizer. Pfizer paid for editorial/medical writing support. M. Dougados, MD, Paris Descartes University, and Department of Rheumatology-Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; E. Wood, MSc, Statistical Consultancy, Quanticate Ltd.; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, and Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; A. Dubanchet, MD, Pfizer; I. Logeart, MD, Pfizer; D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center. Address correspondence to Dr. M. Dougados, Rheumatology B Department, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail: maxime.dougados@cch.aphp.fr. Accepted for publication August 14, 2015.
Laure Gossec
From the Paris Descartes University; Department of Rheumatology-Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP); Institut national de la santé et de la recherche médicale (INSERM; U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique; Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; Pfizer, Paris, France; Statistical Consultancy, Quanticate Ltd., Hitchin, UK; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. Sponsored by Pfizer. Dr. Dougados has received consulting fees from Pfizer and his department has received research grants from Pfizer for this study. Ms. Wood was contracted and paid by Pfizer to provide statistical input to the study and manuscript. Dr. Gossec has received consulting fees from Pfizer. Dr. van der Heijde has received consulting fees and/or research grants from Pfizer. Dr. Dubanchet and Dr. Logeart are employees of Pfizer. Pfizer paid for editorial/medical writing support. M. Dougados, MD, Paris Descartes University, and Department of Rheumatology-Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; E. Wood, MSc, Statistical Consultancy, Quanticate Ltd.; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, and Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; A. Dubanchet, MD, Pfizer; I. Logeart, MD, Pfizer; D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center. Address correspondence to Dr. M. Dougados, Rheumatology B Department, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail: maxime.dougados@cch.aphp.fr. Accepted for publication August 14, 2015.
Arnaud Dubanchet
From the Paris Descartes University; Department of Rheumatology-Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP); Institut national de la santé et de la recherche médicale (INSERM; U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique; Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; Pfizer, Paris, France; Statistical Consultancy, Quanticate Ltd., Hitchin, UK; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. Sponsored by Pfizer. Dr. Dougados has received consulting fees from Pfizer and his department has received research grants from Pfizer for this study. Ms. Wood was contracted and paid by Pfizer to provide statistical input to the study and manuscript. Dr. Gossec has received consulting fees from Pfizer. Dr. van der Heijde has received consulting fees and/or research grants from Pfizer. Dr. Dubanchet and Dr. Logeart are employees of Pfizer. Pfizer paid for editorial/medical writing support. M. Dougados, MD, Paris Descartes University, and Department of Rheumatology-Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; E. Wood, MSc, Statistical Consultancy, Quanticate Ltd.; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, and Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; A. Dubanchet, MD, Pfizer; I. Logeart, MD, Pfizer; D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center. Address correspondence to Dr. M. Dougados, Rheumatology B Department, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail: maxime.dougados@cch.aphp.fr. Accepted for publication August 14, 2015.
Isabelle Logeart
From the Paris Descartes University; Department of Rheumatology-Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP); Institut national de la santé et de la recherche médicale (INSERM; U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique; Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; Pfizer, Paris, France; Statistical Consultancy, Quanticate Ltd., Hitchin, UK; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. Sponsored by Pfizer. Dr. Dougados has received consulting fees from Pfizer and his department has received research grants from Pfizer for this study. Ms. Wood was contracted and paid by Pfizer to provide statistical input to the study and manuscript. Dr. Gossec has received consulting fees from Pfizer. Dr. van der Heijde has received consulting fees and/or research grants from Pfizer. Dr. Dubanchet and Dr. Logeart are employees of Pfizer. Pfizer paid for editorial/medical writing support. M. Dougados, MD, Paris Descartes University, and Department of Rheumatology-Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; E. Wood, MSc, Statistical Consultancy, Quanticate Ltd.; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, and Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; A. Dubanchet, MD, Pfizer; I. Logeart, MD, Pfizer; D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center. Address correspondence to Dr. M. Dougados, Rheumatology B Department, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail: maxime.dougados@cch.aphp.fr. Accepted for publication August 14, 2015.
Désirée van der Heijde
From the Paris Descartes University; Department of Rheumatology-Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP); Institut national de la santé et de la recherche médicale (INSERM; U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique; Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; Pfizer, Paris, France; Statistical Consultancy, Quanticate Ltd., Hitchin, UK; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. Sponsored by Pfizer. Dr. Dougados has received consulting fees from Pfizer and his department has received research grants from Pfizer for this study. Ms. Wood was contracted and paid by Pfizer to provide statistical input to the study and manuscript. Dr. Gossec has received consulting fees from Pfizer. Dr. van der Heijde has received consulting fees and/or research grants from Pfizer. Dr. Dubanchet and Dr. Logeart are employees of Pfizer. Pfizer paid for editorial/medical writing support. M. Dougados, MD, Paris Descartes University, and Department of Rheumatology-Hôpital Cochin, AP-HP, and INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; E. Wood, MSc, Statistical Consultancy, Quanticate Ltd.; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, and Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; A. Dubanchet, MD, Pfizer; I. Logeart, MD, Pfizer; D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center. Address correspondence to Dr. M. Dougados, Rheumatology B Department, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail: maxime.dougados@cch.aphp.fr. Accepted for publication August 14, 2015.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis
Maxime Dougados, Emily Wood, Laure Gossec, Arnaud Dubanchet, Isabelle Logeart, Désirée van der Heijde
The Journal of Rheumatology Nov 2015, jrheum.150378; DOI: 10.3899/jrheum.150378
Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis
Maxime Dougados, Emily Wood, Laure Gossec, Arnaud Dubanchet, Isabelle Logeart, Désirée van der Heijde
The Journal of Rheumatology Nov 2015, jrheum.150378; DOI: 10.3899/jrheum.150378